FDA Removes Partial Clinical Hold on VG-3927 for Microglial Dysfunction in Alzheimer Disease

Published Date: 09 Jan 2025

Results from Vigil Neuroscience’s ongoing phase 1 trial of VG-3927 in healthy volunteers supported the continued development of the therapy as a potential once-daily oral treatment for Alzheimer disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot